Articles

Lilly Wins NAD Fight Over Noom GLP-1 Ads

Eli Lilly has successfully challenged Noom's claims regarding GLP-1 dosing, impacting the competitive landscape in the pharmaceutical sector. This article explores the implications of this legal victory.

EuropaBio's Stance on Food and Feed Safety Omnibus: Implications for Pharma

This article examines EuropaBio's position on the Food and Feed Safety Omnibus and its potential impact on the pharmaceutical sector.

Tyra's Awareness Day: A New Era for Rare Cancer Advocacy

Tyra's recent awareness day highlights the importance of patient advocacy in rare cancer treatment. This event marks a significant step for pharmaceutical engagement.

EUROoCS Annual Meeting 2026: What to Expect

The EUROoCS Annual Meeting 2026 promises to be a pivotal event for B2B stakeholders in the pharmaceutical industry. With a focus on critical data and emerging trends, attendees can expect valuable insights.

Roche's Elevidys: A New Hope for DMD Gene Therapy Approval

Roche aims for EMA approval of Elevidys, a gene therapy for DMD, amidst regulatory challenges. This article analyzes the implications for investors and pharma teams.

Ogilvy Health's Insights on AI and Nano Influencers

This article delves into Ogilvy Health's insights on the fast-paced advancements in AI and the growing significance of nano influencers in pharma marketing.

Roche's Licensing Deal for Xofluza: Implications and Insights

Roche has signed a significant licensing deal for Xofluza with the Medicines Patent Pool, impacting 129 countries. This article explores the implications for the pharma industry.

Gilead's $140M Deal with Yuhan: Implications for Pharma

Gilead Sciences has signed a $140M deal with Korean API manufacturer Yuhan. This article explores the implications for pharma teams and investors.

Ipsen's Transition Challenges: Insights for Pharma Teams

Ipsen faces challenges in managing the transition of teens to adult care. This article explores the implications for pharmaceutical teams.

CG Life's Strategic C-Suite Expansion: Collette Douaihy's Appointment

CG Life's recent appointment of Collette Douaihy as Chief Creative Officer marks a significant step in its C-suite buildout, aiming to enhance its creative direction in the pharma sector.

Germany's Bioeconomy Dialogue: Implications for Pharma

This article examines the recent position paper from Germany's BMWE on the European GMO legal framework, focusing on its impact on the pharmaceutical industry.

Pharma Partnering EU 2026: Key Insights and What to Expect

Pharma Partnering EU 2026 is set to be a pivotal event for B2B interactions in the pharmaceutical sector. Here's what you need to know before it starts.

MaaT Pharma's Regulatory Update on MaaT013 (Xervyteg®)

MaaT Pharma has provided a significant update regarding the marketing authorization application for MaaT013 (Xervyteg®). This article explores the implications for investors and pharma teams.

Pharma Partnering EU 2026: Key Insights and Pre-Event Coverage

Pharma Partnering EU 2026 promises to be a pivotal event for B2B stakeholders in the pharmaceutical industry. Get ready for insights on key players, catalysts, and trends.

IMPHARMA2026: Your Essential Preview of the Upcoming Event

IMPHARMA2026 is set to take place in Copenhagen from June 15-17, 2026. This event promises to be a pivotal moment for B2B stakeholders in the pharma industry.

HLTH Europe 2026: What to Expect from the Upcoming Event

HLTH Europe 2026 is set to be a pivotal event for B2B stakeholders in the healthcare industry. With a focus on innovation and collaboration, this event promises to deliver valuable insights.

SLAS Europe 2026: What to Expect from the Premier Pharma Event

SLAS Europe 2026 is set to be a pivotal event for the pharma industry, taking place in Vienna, Austria. This article previews key takeaways, companies to watch, and essential questions for attendees.

AstraZeneca's FDA Approval: Implications for Hypertension and Fasenra

AstraZeneca secures FDA approval for hypertension, enhancing Fasenra's market potential. Discover the implications for investors and pharma teams.

Biodefence & Biosecurity: EuropaBio's New Task Force

EuropaBio has launched a dedicated Task Force focusing on biodefence and biosecurity. This article explores its significance for the pharmaceutical sector.

Global Pharma Tech 2026: What to Expect at the Event

The Global Pharma Tech 2026 event promises to be a pivotal gathering for industry leaders. Attendees can expect valuable insights into emerging technologies and trends.